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Oral–gastric delivery of vaccines is a preferred route of immunization and is particularly relevant to the development of
vaccine-vector systems. We have investigated the ability of a replication deficient (E1-deleted) adenovirus construct (RAd68),
which efficiently expresses the measles virus nucleocapsid (N) protein under the control of the strong HCMV IE promoter,
to elicit antibody and cytotoxic T cell (CTL) responses in mice following intragastric administration. Measles virus N
protein-specific CTL memory and serum antibody responses were analyzed in a total of 140 mice at time points 2–51 weeks
after immunization either with a single dose of 108 pfu RAd68 or with a fivefold higher dose. Of the 20 animals analyzed in
the first 4-week period following low-dose immunization, 6 mounted low-level splenic CTL responses while 13 animals had
CTL in the mesenteric lymph nodes. Splenic CTL responses were largely undetectable at later times. Only 23% of
low-dose-immunized mice made serum antibody responses and these were generally of low magnitude and frequently of
short duration. In contrast, the majority of animals immunized orally with 5  108 pfu RAd68 mounted splenic CTL responses
(70%) and/or antibody responses (89%). Notably, these responses were stronger and of greater duration than those seen
following immunization at the lower dose. Gut mucosal immunization with replication deficient adenoviruses is a promising
approach, not only for the development of complementary measles vaccine strategies which may be required for measlesINTRODUCTION
The properties of adenovirus vectors have recently been
extensively reviewed (Carroll et al., 2001; Russell, 2000). As
well as being able to express high levels of transgene
products, these vectors are particularly attractive since they
can stimulate long-term humoral and cellular immune re-
sponses directed to the expressed product (Juillard et al.,
1995). Importantly, both systemic and local immune re-
sponses can be induced with such vectors (Gallichan and
Rosenthal, 1996; Xiang and Ertl, 1999). Oral administration
of live adenovirus has been used successfully for many
years in the United States as a vaccine strategy for the
prevention of acute respiratory disease in military recruits
(Rubin and Rorke, 1994). The Ad4 and Ad7 strains associ-
ated with respiratory tract infection were found to replicate
in the gut in the absence of disease induction, thus remov-
ing the need for specific attenuation (Chanock et al., 1966).
However, oral immunization with recombinant adenovi-
ruses to induce transgene-specific responses has received
surprisingly little attention. This strategy has been em-
ployed mainly with replication competent viruses where the
expression of the transgene is driven by an endogenous
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210adenovirus promoter (Lubeck et al., 1989; Prevec et al.,
1990; Both et al., 1993; Flanagan et al., 1997).
Replication deficient vectors have distinct advantages
for immunization including enhanced safety and contain-
ment properties. This may be particularly relevant for use
in populations that may contain immunocompromised
individuals. In addition, because cell to cell spread is not
a requirement, such vectors may be less influenced by
preexisting immunity and, indeed, are less likely to stim-
ulate strong anti-vector immunity themselves.
In this report we have examined the ability of an E1
replication defective human adenovirus 5 recombinant
expressing the measles virus nucleocapsid protein (MV
N) under the control of the HCMV major IE promoter
(Fooks et al., 1995) to induce persistent humoral and
memory cytotoxic T lymphocyte (CTL) responses in mice
following oral administration at two different doses. We
selected the measles virus nucleocapsid protein as a
model antigen for this study as our laboratory has a
long-standing interest in the development of complemen-
tary measles virus vaccine strategies (Fooks et al., 2000).
RESULTS
MV N protein-specific CTL responses in mice
immunized with 108 pfu RAd68virus eradication, but also generally for vaccination agains
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antibody; CTL.
Following oral immunization of a total of 70 mice each
with 108 pfu of recombinant adenovirus expressing mea-t other
ovirus;
on
sles virus nucleoprotein (RAd68), the longevity of any
CTL responses was analyzed in groups of 10 mice on 7
occasions up to 51 weeks. After restimulation of effector
cells in vitro with the N-protein CTL epitope, NP9, splenic
responses were detected in only 7 of 70 mice analyzed.
These responses were low level and, with the exception
of 1 animal, seen only during the first month (Fig. 1). In
contrast, 7 of 10 mice examined at week 2 and 6 of 8 (no
cells recovered from 2 mice) examined at week 4 had
CTL responses in the mesenteric lymph nodes (Fig. 2).
Of the 13 animals with mesenteric CTL, only 2 (at week
4) had splenic responses. At week 8, insufficient viable
cells were recovered for analysis after restimulation of
mesenteric lymphocytes with peptide.
MV N protein-specific CTL responses in mice
immunized with 5  108 pfu RAd68
Oral immunization with the higher dose of RAd68 in-
duced splenic responses in 48 of 69 mice tested (1
mouse died during the study of causes unrelated to
immunization). Furthermore, responses were higher than
those seen following low-dose immunization (Fig. 1). By
week 4, the majority of animals had responded and the
mean lytic activity had increased from that seen at week
2. Mean responses remained high throughout the course
of the experiment, with the exception of results obtained
at week 13 (when fewer mice responded). On this occa-
sion, however, only 1 of 2 control mice, inoculated intra-
peritoneally, responded, whereas on every other occa-
sion both the positive controls had CTL activity. By week
51 the frequency of splenic CTL responsiveness was
reduced, although the magnitude of the response had
not diminished.
In contrast to mice inoculated orally at the lower dose,
only 4 of 10 animals examined at week 2 had mesenteric
lymph node CTL responses, which, in general, were
weaker than those responses seen in the low-dose
group. Two animals had mesenteric CTL in the absence
of splenic activity. By week 4 mesenteric responses were
undetectable in 5 mice from which viable mesenteric
FIG. 1. Measles virus N protein-specific splenic CTL activity following oral immunization with RAd68. Mean  standard deviation percentage
specific lysis of measles virus NP9 peptide-pulsed autologous target cells in responding mice is shown following immunization with a single dose
of either 108 pfu RAd68 (E) or 5  108 pfu Rad68 (F). Specific precursors were expanded in vitro by incubation with NP9 peptide. The means were
calculated from the positively responding animals only. Responses were assigned as positive where they exceeded the mean background level of
killing determined in splenocytes from 18 naive mice by two standard deviations. The proportion of mice responding at each time is shown. ,
Background killing of autologous targets in the absence of peptide.
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lymphocytes were recovered following culture, although
all 5 had splenic responses. As in the low-dose group, no
viable mesenteric lymphocytes were recovered at week
8 following restimulation in vitro.
In all experiments, lymphocytes from naive mice were
unreactive in the CTL assay.
MV N protein-specific serum antibody responses in
mice immunized with 108 pfu RAd68
Measles virus N protein-specific antibody responses
were detected in 16 of 70 mice. In general, antibody
responses were weak (Fig. 3). Of the 7 animals positive
FIG. 2.Measles virus N protein-specific CTL activity in mesenteric lymphocytes early after oral administration of RAd68. Mean standard deviation
percentage specific lysis of measles virus NP9 peptide-pulsed autologous target cells in responding mice is shown following immunization with a
single dose of either 108 pfu RAd68 (E) or 5  108 pfu Rad68 (F). The means were calculated from the positively responding animals only. Responses
were assigned as positive where they exceeded the mean level of killing determined in mesenteric lymph nodes from six naive mice by two standard
deviations. The proportion of mice responding at each time is shown. , Background killing of autologous targets in the absence of peptide.
FIG. 3. Longitudinal analysis of measles virus N protein-specific serum antibody titers following oral immunization with RAd68. IgG responses
specific for measles virus N protein were measured by ELISA. Mean end point titers one standard deviation are shown following immunization with
a single dose of either 108 pfu RAd68 (E) or 5  108 pfu RAd68 (F). Means were calculated from the positively responding animals only. Responses
were assigned as positive where titers exceeded 100. The proportion of mice responding at each time point is indicated.
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at week 2, 3 had titers below the threshold of detection
at week 4; another animal had a reduced titer and in only
2 animals was a rising titer detected. Six animals in
which antibody was not detected at week 2 became
seropositive by week 4 (titers 162–1071). Another 3 ani-
mals responded between weeks 4 and 8. Antibody re-
sponses were, in general, transient: by week 13, all but 1
responder had falling titers.
The overall pattern of antibody and CTL responses is
summarized in Table 1. All animals that had splenic CTL
responses made persistent antibody responses, with
one exception. In this animal, which never made an
antibody response, a CTL response was detected at
week 26. Of the 11 animals at weeks 2 and 4 in which
CTL responses were detected in the mesenteric lymph
nodes but not in the spleen, only 3 had weak antibody
responses. In 2 of these animals sacrificed at week 4,
antibodies were detected only at week 2. A further 7
animals, sacrificed from week 8 onward for CTL analysis,
had antibody responses in the absence of splenic CTL
responses; although in only 4 instances were MV-N-
specific antibodies detectable at the time of CTL analy-
sis. Of the 3 CTL nonresponders with antibody at week 8,
only 1 had previous evidence of seroconversion.
MV N protein-specific serum antibody responses in
mice immunized with 5  108 pfu RAd68
Measles virus N protein-specific antibody responses
were detected in 62 of 70 mice. In general, in contrast to
responses in animals given 108 pfu, responses were high
(Fig. 3). Three mice that were seronegative at week 2 had
seroconverted by week 4. Of the 8 animals in which
antibody was never detected, 5 were killed at week 2 (for
CTL analysis). One other seronegative animal was killed
at week 8 and the final 2 animals were unresponsive for
the whole period of the experiment.
All CTL responders, including 2 animals at week 2 that
only had CTL responses detectable in mesenteric lymph
nodes, made antibody responses with the exception of 1
animal analyzed at week 2 (that had both a splenic and
a mesenteric lymph node CTL response). Thirteen CTL
nonresponders had antibody responses. The mean anti-
body titers measured over time were lower in this group
of animals compared to the titers in animals in which a
CTL response was elicited but this difference did not
reach statistical significance.
Antibody titers from unvaccinated mice fell below the
threshold of detection at all time points.
DISCUSSION
Previous studies of oral immunization with recombi-
nant adenoviruses have largely focused on replication
competent constructs. Oral (intragastric) immunization of
mice with E3 recombinant adenovirus expressing rota-
virus VP7 induced serum antibody responses, but these
were at a lower level than those seen following intraperi-
toneal, intravenous, or intranasal delivery (Both et al.,
1993). Similarly, an E3 construct expressing rabies virus
glycoprotein induced neutralizing antibodies in mice fol-
lowing oral administration, but only a proportion of mice
responded and the titers were low compared with those
in an intraperitoneally inoculated group (Prevec et al.,
1990). In another murine study, an E3 construct ex-
pressing simian immunodeficiency virus Gag p55 in-
duced antibody in fewer than half of the mice immunized;
CTL responses were also detected and in some animals
were detected in the absence of a serum antibody re-
sponse (Flanagan et al., 1997). In chimpanzees, a spe-
TABLE 1
Distribution of Measles Virus N Protein-Specific CTL and Antibody Responses in Individual Mice
Week
Number of mice responding



















2 2 6 0 2 10 5 1 0 4 10
4 7 2 0 1 10 9 0 1 0 10
8 0 0 3 7 10 9 0 0 1 10
13 0 0 2 8 10 5 0 5 0 10
26 0 1 0 9 10 8 0 2 0 10
36 0 0 2 8 10 10 0 0 0 10
51 0 0 1 9 10 3 0 4 2 9
a Animals immunized with 108 pfu RAd68.
b Animals immunized with 5  108 pfu RAd68.
c Indicates a positive response detected in spleen and/or mesenteric lymph nodes.
d Indicates antibody response detected at any time after immunization.
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cies fully permissive for the replication of human adeno-
viruses, sequential oral administration of E3 constructs
expressing hepatitis B surface antigen induced low lev-
els of antibody (Lubeck et al., 1989). However, in a small
human clinical trial, oral administration of one of these
constructs failed to induce transgene-specific immunity
(Tacket et al., 1992). Overall, replication-competent ad-
enoviruses appear to require a degree of active replica-
tion in the vaccinated host in order to stimulate effective
transgene-specific immune response (Lubeck et al.,
1997; Buge et al., 1997). In the present study, an E1
replication deficient construct was used that is capable
of high level expression of MV N protein driven by the
strong HCMV major IE promoter. Previous studies have
shown this construct to elicit transgene-specific humoral
and CTL immunity in mice following parenteral vaccina-
tion (Fooks et al., 1995). A striking finding following oral
delivery of this construct was the influence of dose on
the responses obtained. Systemic humoral and CTL re-
sponses were weaker, of short duration, and of much
lower frequency following administration of 108 pfu,
whereas at a fivefold higher dose, much stronger, per-
sistent responses were observed in the majority of ani-
mals tested. This dose dependency probably accounts
for the failure of a replication deficient adenovirus con-
struct expressing rabies virus glycoprotein to elicit a
measurable serum antibody response following oral im-
munization of mice with 106 pfu (Xiang et al., 1996). We
have previously reported a strong dose-dependent effect
following systemic immunization of mice with an HIV-1
env/rev-expressing construct; however, in this instance a
single immunization induced CTL memory in the ab-
sence of an antibody response (Bruce et al., 1999). A
similar finding was reported by Flanagan et al. (1997)
following oral administration of an SIV Gag p55-express-
ing replication competent construct. The MV N protein
may be a more potent B-cell immunogen, as the protein
can self assemble into nucleocapsid-like structures
within RAd68-infected cells (Fooks et al., 1995). Virus and
virus-like particles expressing repeated B-cell epitopes
are known to efficiently induce T-cell-independent anti-
body responses (Fehr et al., 1998) and persistence of
immune complexed antigen may account for the longev-
ity of the antibody response observed (Bachmann et al.,
1994). Long-term antibody responses may be maintained
by the ongoing differentiation of memory B cells into
antibody-secreting plasma cells. However, it has also
been shown that plasma cells themselves may be long-
lived (Manz et al., 1997; Slifka et al., 1998) and can
survive independently of antigen (Manz et al., 1999).
Likewise, longevity of the N protein-specific CTL memory
responses may also either be due to persistence of
antigen, although even with replication-competent con-
structs expression may be relatively short-lived (Mittal et
al., 1993), or memory pCTL may be maintained in the
absence of specific or cross-reactive antigenic stimula-
tion (Murali-Krishna et al., 1999). Interestingly, the lower
dose of RAd68 induced a stronger response at higher
frequency in mesenteric lymph nodes shortly after infec-
tion than did the higher dose, often in the absence of a
splenic response. Surprisingly, by week 4 mesenteric
responses were undetectable in animals given the
higher dose of virus despite the efficient generation of
splenic responses. The generation of long-lived splenic
memory CTL responses following oral delivery differs
from the findings reported following intranasal delivery of
a replication competent adenovirus expressing herpes
simplex glycoprotein B. In that study, memory CTL re-
sponses were detected locally and systemically at early
times, as in the present study; however, after several
months a local memory response persisted in the ab-
sence of a splenic memory response (Gallichan and
Rosenthal, 1996). Our results suggest that the magnitude
of the dose given orally may determine the distribution of
the CTL memory response. Replication deficient adeno-
viruses can transduce enterocytes and can express
transgenes at a high level in epithelial cells, possibly M
cells, overlying lymphoid follicle domes in the distal il-
eum (Foreman et al., 1998). Thus, persistence of expres-
sion at these sites may efficiently stimulate immune
responses. The apparent disappearance of local reactiv-
ity may be due to the presence of effector cells stimu-
lated in vivo that would undergo apoptosis under condi-
tions of in vitro restimulation. In future studies this pos-
sibility could be addressed by analysis of CD8 cell
reactivity directly ex vivo using sensitive assays such as
Elispot, intracellular cytokine staining, or staining with
MHC–peptide tetrameric complexes. We cannot exclude
the possibility that at high doses of virus there is a
degree of breakthrough of virus replication. High multi-
plicity infection in vitro with RAd68 leads to expression of
adenovirus structural proteins (A. Fooks, unpublished
observation). However, given the size of the target cell
population in the gut, it would seem unlikely that such
conditions would occur in vivo. Further studies using in
situ labeling techniques and virus rescue are needed to
fully address these issues of antigen persistence and
localized virus replication in this model system.
Our results show that the oral (intragastric) route is
efficient for the stimulation of persistent immune re-
sponses to a transgene expressed from a replication
deficient adenovirus following a single administration
and may stimulate systemic and local responses in a
dose-dependent manner. In this study we did not analyze
local antibody responses; however, we believe that our
results are sufficiently encouraging to stimulate further
studies in this area. Oral delivery of DNA by this vector is
much more efficient than administration of either naked
DNA (Etchart et al., 1997) or DNA, encoding the same
antigen, encapsulated in biodegradable microspheres
(Fooks et al., 2000). In addition to the potential of this
vaccination strategy as a complementary approach in
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the eradication of measles virus, oral/gastric delivery of
recombinant replication deficient adenovirus constructs
in a single dose has great potential in vaccination




The construction of the adenovirus recombinant
(RAd68) expressing the MV nucleocapsid protein has
been described previously (Fooks et al., 1995). Briefly, the
intact N gene of the Edmonston-P9 strain of MV was
placed under the control of the HCMV IE promoter and
recombined into the E1 region of human adenovirus 5
vector. Stocks of RAd68 were prepared following plaque
purification on 293 cells that provide E1a in trans, thus
allowing production of progeny virus. Titers were ex-
pressed as pfu determined on 293 cells.
L929 cells (H-2k), used as targets in CTL assays, were
grown as monolayers in complete Glasgow modified
Eagle’s medium supplemented with 10% (v/v) fetal calf
serum and 0.3% (v/v) L-glutamine.
Immunization of mice
Animals were housed in accordance with the Home
Office Code of Practice (1984) and licensed procedures
carried out in accordance with the Animals (Scientific
Procedures) Act 1986. Adult, 6- to 8-week-old C3H/He
mice (Harlan-Olac) were immunized with RAd68 using a
single dose containing 108 pfu (70 mice) or 5  108 pfu
(70 mice). For oral immunization, food was withheld for
6 h before administration of virus (diluted to a final
volume of 500 l with 0.1 M bicarbonate buffer, pH 8.9) by
gavage using a stainless-steel 22-gauge oral dosing
cannula. Control groups of mice were immunized intra-
peritoneally with 108 pfu RAd68 in 100 l of phosphate-
buffered saline. Each mouse was individually earmarked
for identification purposes prior to immunization. Groups
of 10 mice from each immunization schedule were hu-
manely sacrificed at weeks 2, 4, 8, 13, 26, 36, and 51
postvaccination and spleens were removed for use in
the CTL assay. In addition, mesenteric lymph nodes were
removed from animals sacrificed at weeks 2, 4, and 8 for
CTL analysis. Tail bleeds were taken for serum antibody
analysis from all of the mice remaining in the study at the
same time points.
Serological analysis
IgG responses specific for MV N protein were ana-
lyzed by ELISA using baculovirus-expressed N protein as
antigen as described previously (Warnes et al., 1994).
End-point titers were expressed as the reciprocal of the
dilution of serum corresponding to a defined absorbancy
on the linear region of the dose–response curve.
Analysis of CTL responses
CTL activity was assessed following expansion in vitro
of specific precursors (pCTL) using the MV-N H-2Kk re-
stricted CTL epitope (NP9) VESPGQLI (Beauverger et al.,
1994). Alongside the orally immunized animals, CTL ac-
tivity was also assessed at each time point in two mice
immunized intraperitoneally 2 weeks earlier with 108 pfu
RAd68 and in two naive animals (positive and negative
assay controls). Splenocytes (at every time point) and
lymphocytes from mesenteric lymph nodes (at weeks 2,
4, and 8) were isolated from individual mice and ex-
panded separately. Splenocytes were cultured in 10 ml
and mesenteric lymphocytes in 1 ml of lymphocyte me-
dium (RPMI 1640 supplemented with 10% fetal calf se-
rum, penicillin/streptomycin 100 U/ml, 20 mM HEPES,
and 15 mM -mercaptoethanol) in the presence of the
NP9 peptide at 5 g/ml. On day 3, cultures were supple-
mented with Lymphocult T (Biotest, UK) at 10 IU/ml and
CTL activity was assessed on day 7 by chromium re-
lease assay.
On the day of assay, effector cells were washed three
times, suspended in lymphocyte medium and in tripli-
cates (splenocytes) or duplicates (mesenteric lympho-
cytes), diluted twofold in U-bottom wells (96-well plate;
Nunc) to give effector to target ratios of 100:1, 50:1, and
25:1 for splenocytes and between 13:1 and 90:1 for mes-
enteric lymphocytes depending upon recovery of viable
cells. Five thousand 51Cr-labeled, peptide-pulsed L929
target cells were added to the effector cells in lympho-
cyte medium and incubated at 37°C for 5 h. Effector cells
were also combined with targets in the absence of pep-
tide to determine the no-peptide background percentage
lysis. Spontaneous and total chromium releases were
estimated from wells in which target cells were incu-
bated in medium alone or with 5% Triton X-100. The
percentage specific lysis was determined as (sample
release  spontaneous release)/(total release  spon-
taneous release)  100. Only responses that exceeded
the background level of killing by 2 standard deviations
above the mean result from 18 naive mice (splenocytes)
or from 6 naive mice (mesenteric lymphocytes) were
scored as positive.
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